VOR logo

Vor Biopharma Inc. (VOR)

$18.18

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on VOR

Market cap

$1.12B

EPS

299.81

P/E ratio

0.1

Price to sales

--

Dividend yield

--

Beta

1.874484

Price on VOR

Previous close

$18.97

Today's open

$18.96

Day's range

$17.74 - $19.16

52 week range

$6.50 - $26

Profile about VOR

CEO

Robert Ang

Employees

76

Headquarters

Boston, MA

Exchange

Nasdaq Global Select

Shares outstanding

61434344

Issue type

Common Stock

VOR industries and sectors

Healthcare

Biotechnology & Life Sciences

News on VOR

Vor Bio Expands Strategic Partnership with RemeGen, Adding Next Generation, Long-Acting RC298 to BAFF/APRIL Franchise

RemeGen's expertise and next generation engineering expand Vor Bio's leadership in the BAFF/APRIL field RC298 is a next generation, long-acting dual BAFF/APRIL inhibitor designed to combine high potency and extended half-life for potentially best-in-class efficacy and dosing RC298 is in IND-enabling development, with an initial regulatory filing anticipated in the first half of 2027 in China Cash runway reaffirmed into early 2029 BOSTON, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced an amendment to its existing agreement with RemeGen Co., Ltd (HKEX: 9995, SHA: 688331) to add RC298, a next-generation dual BAFF/APRIL inhibitor, to Vor Bio's exclusive license for development and commercialization outside of Greater China. RC298 is an engineered TACI-Fc fusion protein designed to inhibit both BAFF (B cell activating factor) and APRIL (a proliferation-inducing ligand), two key regulators of pathogenic B cell and plasma cell biology.

news source

GlobeNewsWire • Nov 12, 2026

news preview

Vor Bio To Participate in 2026 Jefferies Global Healthcare Conference

BOSTON, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference in London, United Kingdom. Presentation: Tuesday, November 17, 2026 at 10:30am – 10:55 am GMT A live webcast of the presentation may be accessed on the Investors section of the Vor website at ir.vorbio.com.

news source

GlobeNewsWire • Nov 10, 2026

news preview

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on November 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 24,650 shares of Vor Bio's common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 5,300 shares of Vor Bio's common stock to 2 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).

news source

GlobeNewsWire • Nov 4, 2026

news preview

Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Completed enrollment in Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis; topline results remain on track for 1H27

news source

GlobeNewsWire • Oct 30, 2026

news preview

Vor Bio says its experimental drug slowed loss of kidney function in late-stage study

Vor Bio says its experimental drug slowed loss of kidney function in late-stage study

news source

Reuters • Oct 22, 2026

news preview

Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy

Annualized eGFR slope of -0.6 vs. -5.7 mL/min/1.73 m²/year for placebo, a 5.1 mL/min/1.73 m²/year treatment difference (p

news source

GlobeNewsWire • Oct 22, 2026

news preview

Telitacicept Demonstrates Deep and Durable Minimal Symptom  Expression Through 48 Weeks in Generalized Myasthenia Gravis

More than 94% of participants achieved a ≥5-point MG-ADL improvement at Week 48 42% of telitacicept-treated participants achieved minimal symptom expression (MSE) at any time over 48 weeks, increasing from 23.7% over the first 24 weeks After achieving MSE, 86.7% of MSE events were sustained at the next monthly assessment and participants spent 83-85% of remaining study follow-up in MSE Approximately 51% of participants with baseline MG-ADL scores of 6-10 and 21% of participants with baseline MG-ADL scores ≥11 achieved MSE BOSTON, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced a new post hoc analysis from the Phase 3 trial conducted in China by its collaborator, RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), evaluating telitacicept in adults with generalized myasthenia gravis (gMG).

news source

GlobeNewsWire • Sep 29, 2026

news preview

Vor Biopharma: A Funded Replication Story With Franchise Potential

Vor Biopharma is advancing telitacicept globally, leveraging strong Chinese clinical evidence and a robust $514.5M liquidity position. VOR's global Phase 3 trials in myasthenia gravis and Sjögren's are fully enrolled or underway, with topline MG data expected in H1 2027. Competitive pressures from argenx, Amgen, and Novartis require VOR to demonstrate differentiated efficacy, safety, and physician trust for commercial success.

news source

Seeking Alpha • Sep 18, 2026

news preview

Vor Biopharma Inc. (VOR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Vor Biopharma Inc. (VOR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

news source

Seeking Alpha • Sep 9, 2026

news preview

Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis

Topline results from UPSTREAM MG's 24-week primary endpoint remain on track for first half of 2027 Global Phase 3 ocular myasthenia gravis (oMG) registrational trial, UPSTREAM oMG, broadens telitacicept development across the myasthenia gravis (MG) spectrum; first patient dosing anticipated in the first half of 2027 BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the completion of enrollment in UPSTREAM MG, its global Phase 3 registrational trial evaluating telitacicept for the treatment of generalized myasthenia gravis (gMG).

news source

GlobeNewsWire • Sep 8, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Vor Biopharma Inc.

Open an M1 investment account to buy and sell Vor Biopharma Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in VOR on M1